© Pint of Science, 2024. All rights reserved.
Join us at the Hop and Grain for Pint of Science where obesity expert and top science communicator Giles Yeo helps us to understand the latest obesity medications that are taking over the headlines.
Are the new class of GLP1 anti-obesity medications a panacea?
Professor Giles Yeo
(Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge)
GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss. But how do they work, and are these therapeutics the long sought after solution to obesity? Here I will explore the history of these drugs, explain their mechanisms of action, and discuss their importance as a therapeutic for obesity, type 2 diabetes, and heart disease, and crucially, whether or not they are safe in the long term.
Map data © OpenStreetMap contributors.